Leadership Success in IO from Oncologists’ Perspectives

Having recently named the 2020 leaders in oncology and ImmunoOncology, our latest release from our annual Corporate Leadership report reveals the key attributes oncologists view as driving successful leadership in IO.

Click to Enlarge

“Products” and “R&D/Product Pipeline” are the two most important aspects driving oncologists’ view of Corporate Leadership. The top five domains account for 73% of Oncologists’ definition of leadership in ImmunoOncology (IO) and include â€œPatient Support”, “Corporate Commitment” and “Customer Service”.

Engaging oncologists from the EU and US, we found a high consistency in their response but there were also notable differences:

  • US oncologists stressed higher importance on “Customer Service” ranking it 3rd compared to 7th amongst EU oncologists
  • EU oncologists favoured “MSLs / Medical Affairs” higher than their US colleagues (ranking 5th vs 8th in US)

Direct customer engagement performed through life science companies commercial and marketing activities account for 35% of oncologist’s preferred domains.

To get your copy of the 2020 Corporate Leadership report, please click here to request your report copy.

About the study

The 2020 Corporate Leadership Study was conducted with 100 oncologists across US and EU using ONCpulseTM agile research solution. ONCpulseTM answers today’s questions tomorrow through global access to 130,000+ experts and treaters in oncology, hematology and complex rare diseases.

The objectives of the research were to:

  • Define the meaning of ‘corporate leadership’ to the oncology community
  • Reveal the leaders in oncology and ImmunoOncology (IO) to compare/contrast how companies are evaluated by oncologists
  • Assess current barriers and drivers to ImmnoOncology treatment use and identify what oncologists would like to see improved by corporate leaders in the IO space

Clients like you choose MDoutlook as their precision intelligence partner of choice though the winning solutions and team expertise that has garnered praise from across the industry. If you would like your personalized leadership briefing and map out your teams future success, lets take the next step to arrange a meeting using the calendar link or contact us today at [email protected] or call +1.404.496.4136.

Unveiling 2020 Leaders in Oncology & IO

In our latest annual series exploring corporate leadership (in oncology and IO), oncologists shared their views to reveal BMS (and Celgene), Merck & Co and Roche / Genentech as dominant in oncology and ImmunoOncology.

Click on image to enlarge

Today’s corporate leaders dominated in 2019 with oncologist preferences showing consistency in their ranking companies (year on year) with one notable change as Pfizer dropped out the 2020 top 3 leaders in EU oncology.

Oncologists chose to rate corporate leadership across a greater number of companies in oncology compared to a tighter list of companies they rated in ImmunoOncology.

Leadership was determined through triangulation of three robust approaches. IO corporate leadership patterns were more distinct with clear leaders (compared to oncology) across tumor types.

  • BMS ranked first in IO tumor types including AML, Hodgkin’s lymphoma, Multiple myeloma, HCC, Pancreatic, Kidney, Melanoma and Head & Neck cancers
  • Roche / Genentech was rated top in B-cell lymphomas, Breast (including HER2+, HR+ & TN), Bladder and SCLC
  • Merck & Co made IO pole position in Colorectal, NSCLC and Prostate cancer

Around half of US (50%) and EU (58%) oncologists view corporate leadership in IO broadly, and the other half view corporate leadership by individual tumor types.

Our next post will explore attributes oncologists viewed as driving successful corporate leadership.

About the study

The 2020 Corporate Leadership Study was conducted with 100 oncologists across US and EU using ONCpulseTM agile research solution. ONCpulseTM  answers today’s questions tomorrow through global access to 130,000+ experts and treaters in oncology, hematology and complex rare diseases.

The objectives of the research were to:

  • Define the meaning of ‘corporate leadership’ to the oncology community
  • Reveal the leaders in oncology and ImmunoOncology (IO) to compare/contrast how companies are evaluated by oncologists
  • Assess current barriers and drivers to ImmunoOncology treatment use and identify what oncologists would like to see improved by corporate leaders in the IO space

Want to find out more? Click here to get your copy of the 2020 Corporate Leadership report .

We breed client confidence as a leading precision intelligence company through winning solutions and team expertise. Lets discuss your and your teams future leadership success. Take the next step to arrange a meeting using the calendar link or contact us today at [email protected] or call +1.404.496.4136.